Skip to content

ADMA Biologics ADMA Long-Term Debt

Long-Term Debt at other companies

Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
$802.9M-33.1%
Quest Diagnostics logo
Quest DiagnosticsDGX
$5.16B-12.0%
Biohaven logo
BiohavenBHVN
$241.91M
Amgen logo
AmgenAMGN
$51.89B-3.9%
TG Therapeutics logo
TG TherapeuticsTGTX
$745.14M+204%
Adaptive Biotechnologies logo
Adaptive BiotechnologiesADPT
$124.75M-5.2%

Other financials

Income statement

See full
Revenue$114.5M-0.3%
Gross profit$80.8M+32.2%
Operating income$58.3M+67.1%
Net income$45.3M+68.5%
EPS (diluted)$0.19+72.7%

Balance sheet

See full
Cash & equivalents$138.2M+92.9%
Total debt$204.4M+2,055%
Total equity$390.3M+4.5%
Total assets$665.2M+30.3%

Cash flow

See full
Operating cash flow$58.2M+396%
CapEx$2.5M-45.9%
Free cash flow$55.7M+329%

Valuation

See full
Market cap$2.01B-54.5%
Enterprise value$2.08B-52.5%
P/E12.2×-9.2×
P/S-5.7×

Profitability

See full
Gross margin61.3%+8.7pp
Operating margin42.1%+9.0pp
Net margin32.4%-12.6pp
FCF margin21.2%+1.4pp

Returns & leverage

See full
Return on equity43.3%-35.2pp
Debt / equity0.5×+0.5×
Current ratio+0.4×

Where this comes from

Reported directly by ADMA Biologics in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebtNoncurrent.

The official record: ADMA Biologics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about ADMA Biologics's long-term debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ADMA Biologics's long-term debt?
ADMA Biologics (ADMA) reported long-term debt of $193.58M in Q1 2026.
What is the long-term trend for ADMA Biologics's long-term debt?
Over 2 years (2020 to 2025), ADMA Biologics's long-term debt has grown at a -13.6% compound annual growth rate (CAGR), from $92.97M to $69.33M.
What does long-term debt mean?
Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.